Omar Al Dhaybi, MD, MSc, FASN, is a Hypertension specialist and Director of the American Heart Association Comprehensive Hypertension Center at Mount Sinai Fuster Heart, where he serves as Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

 

He completed his nephrology fellowship at the University of Chicago, followed by advanced subspecialty training in hypertension at the American Heart Association Comprehensive Hypertension Center at the University of Chicago under Dr. George Bakris. Dr. Al Dhaybi is board certified in hypertension by the American Heart Association. His clinical practice and research focus on resistant and secondary hypertension, including hypertension associated with chronic kidney disease, hypertension associated with endocrine disorders, renovascular disease, autonomic disorders, and hypertension in pregnancy.

James L. Januzzi, M.D. is the Adolph Hutter Professor of Medicine at Harvard Medical School and has been a member of the Massachusetts General Hospital Cardiology Division since 2000, where he directs the Dennis and Marilyn Barry Fellowship in Cardiology Research. He is also the Chief Scientific Officer and C. Michael Gibson Chair at the Baim Institute for Clinical Research.

 

Dr. Januzzi completed his residency in internal medicine at Brigham and Women’s Hospital, followed by a cardiology and echocardiography fellowship at Massachusetts General Hospital, and is board certified in internal medicine by the American Board of Internal Medicine. His clinical practice focuses on heart failure and chronic coronary artery disease, and his research focuses on cardiac biomarker testing. Dr. Januzzi has published more than 1000 manuscripts, is routinely among the top 1% most cited authors in cardiology and was named the 2024 ACC Distinguished Clinical Researcher.

Luke J. Laffin, MD is a preventive cardiologist and hypertension specialist in the Preventive Cardiology & Rehabilitation Section of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute, Cleveland Clinic, where he has been on staff since 2018.  He is also the Medical Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) and an Associate Professor of Medicine within the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. 

​

Dr. Laffin's clinical and research focus centers on hypertension, lipid disorders, obesity, and cardiometabolic disease. He currently serves as the Chair of the Steering Committee for Retension's NORMALIZE-1 trial. 

​

Dr Laffin earned his medical degree from Vanderbilt University School of Medicine, completed his residency at the University of Chicago, and went on to complete fellowships there in hypertensive diseases and cardiovascular disease.

Professor Ian Wilkinson, MD is an experienced clinical pharmacologist and researcher in hypertension and cardiovascular disease, serving as Professor of Therapeutics at the University of Cambridge, where he leads the Division of Experimental Medicine and Immunotherapeutics and directs the Cambridge Clinical Trials Unit and the Office of Translational Research. He is also an Honorary Consultant Physician in Clinical Pharmacology and General Medicine at Cambridge University Hospitals.

​

Professor Wilkinson's research centers on the physiology and pharmacology of the cardiovascular system, with a particular focus on hypertension, arterial stiffness, and endothelial function. Over more than 25 years, he has led numerous national and international trials and studies aimed at understanding the causes of hypertension and identifying optimal treatments, and his group has developed research partnerships with a range of pharmaceutical and device companies.

 

He currently serves as President of the British and Irish Hypertension Society, where he has helped lead the development of national hypertension guidelines. He is a Fellow of both the British Hypertension Society and the British Pharmacological Society, and a Fellow of the American Heart Association.

Randal M. Zusman, MD is the Director of the Division of Hypertension at the Massachusetts General Hospital Heart Center in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School. Dr. Zusman has been designated a Specialist in Clinical Hypertension by the American Society of Hypertension. Dr. Zusman's primary clinical interests are in the evaluation and treatment of patients with hypertension (high blood pressure), hypercholesterolemia, atrial fibrillation, and angina pectoris, and in cardiac risk reduction strategies.

​

Dr. Zusman received his M.D. from Yale University School of Medicine and completed his internship, residencies and chief residency at Massachusetts General Hospital. He completed fellowships at the National Heart, Lung and Blood Institute, and in the Cardiology Unit, Massachusetts General Hospital.